A claims-based endometriosis study identifies benzodiazepine co-prescribing within a broader pattern of chronic opioid treatment.
Women with endometriosis had higher odds of chronic opioid use and recorded opioid-related complications than comparison patients. Among chronic users, dose and days supplied increased over time, and benzodiazepine or other sedative prescriptions were also observed. The analysis therefore raises questions about cumulative prescribing trajectories.
The data came from commercially insured patients, and claims do not demonstrate simultaneous ingestion. The reported associations with endometriosis or chronic opioid use cannot be assigned specifically to benzodiazepines. Pain severity and other comorbidities may influence both prescribing and outcomes.
For a combined-drug case, build a dated medication-overlap history rather than assuming every prescription was used together. The paper supports reviewing escalation, co-prescribing, and monitoring. It does not quantify a benzodiazepine-specific causal contribution to any individual overdose or fall.
Source reviewed: Chronic opioid use and complication risks in women with endometriosis A cohort study in US administr (PMC8251707). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: Valerian Interaction Claims Need Separate Pharmacokinetic and Sedative Evidence; Japanese Anxiolytic Polypharmacy Claims Lacked the Diagnoses Needed to Explain Prescribing.